Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of BTK-Targeted Protein Degrader BGB-16673 in B-cell Malignancies
jRCT2031240605Phase 2Recruiting
- Sponsor
- BeOne Medicines
- Start
- Apr 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of catadegbrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma (MZL) and 3 more, sponsored by BeOne Medicines. Primary endpoints: Safety and tolerability of BGB-16673 monotherapy, Maximum tolerated dose (MTD) or maximum assessed dose (MAD) and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
catadegbrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)marginal zone B-cell lymphoma (MZL)Waldenström macroglobulinemia (WM)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2031240605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240605.